For reproduction and development hormone testing
Measurement of all fertility hormones is usually performed between day 3 and 5 of a women's hormonal cycle for the diagnosis of menorrhea problems, onset of menopause and infertility. Having to perform each test separately has cost and time implications.
The Randox fertility panel includes follicle-stimulating hormone (FSH), luteinising hormone (LH), estradiol, progesterone, testosterone and prolactin. FSH and LH, produced in the hypothalamus, stimulate the ovaries and the uterus to prepare the female body for ovulation and implantation. Estradiol and progesterone are also involved in this process, but are produced mainly in the ovaries.
All hormones are interdependent on a classic negative feedback mechanism. Testosterone is the main male hormone, but also produced by women in small quantities. Prolactin is produced in the pituitary gland and stimulates the growth of the mammary glands and the production of milk after childbirth. Testing of all co-dependent hormones can give valuable information of a woman's hormonal status. Diagnostically significant values can indicate the cause of the underlying problem, and will instigate further relevant investigation.
All analytes on the fertility array can be measured simultaneously with a small patient sample using Biochip Array Technology. The Evidence analyser offers high throughput testing of the fertility array, the Evidence Investigator is suitable for lower throughput.